Safety and tolerability of once-daily umeclidinium/vilanterol 125/25 mcg and umeclidinium 125 mcg in patients with chronic obstructive pulmonary disease: results from a 52-week, randomized, double-blind, placebo-controlled study - Concepedia

Concepedia

Publication | Open Access

Safety and tolerability of once-daily umeclidinium/vilanterol 125/25 mcg and umeclidinium 125 mcg in patients with chronic obstructive pulmonary disease: results from a 52-week, randomized, double-blind, placebo-controlled study

DOI Full Paper Access

92

Citations

18

References

2014

Year

James F. Donohue, Dennis E. Niewoehner, Jean Brooks, Dianne M. O’Dell, Alison Church

Respiratory Research

Abstract

UMEC/VI 125/25 mcg and UMEC 125 mcg were well tolerated over 12 months in patients with COPD.

References

	Year	Citations

Page 1